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Introduction
Although primary splenic lymphoma (PSL) is ambigu-
ously defined, it probably comprises less than 1% of
non-Hodgkin’s lymphoma (NHL).1 Abdominal dis-
comfort from spleen enlargement is the most common
presentation. Das Gupta et al2 adopted a restrictive
definition of PSL as a lymphoma involving only the
spleen and splenic hilar lymph nodes, but PSL tends
to be asymptomatic until the disease spreads. Without
altering the primariness of the disease, Falk and
Stutte3 defined PSL as generalized lymphoma localized
in the spleen with minimum liver and bone marrow
involvement.
Hemophagocytic lymphohistiocytosis (HLH) is a
rare and fatal disorder; patients usually present with
fever, cytopenia, liver dysfunction, hepatosplenomegaly,
hypertriglyceridemia and hyperferritinemia.4 It is
characterized by accumulation, in the reticuloen-
dothelial system, of activated macrophages showing
phagocytosis of hematopoietic cells. Despite HLH
possibly being associated with infections, autoimmune
diseases and solid malignancies, T cell lymphoma is
still the leading cause of adult HLH.5,6 Here, we
report the case of a 77-year-old man with diffuse large
B cell PSL, who presented with HLH complicated by
spontaneous splenic rupture after chemotherapy. His
PSL was diagnosed in the subsequent emergency
splenectomy.
Case Report
A 77-year-old man presented with intermittent fever
up to 39°C of 3 weeks’ duration. Infection surveys
including blood culture, urine culture and stool cul-
ture were all negative. Splenomegaly with infarction
was found by computed tomography (Figure 1).
Complete blood count revealed leukocytosis (white
blood count, 10.4 × 109/L), anemia (hemoglobin,
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7.4 g/dL) and thrombocytopenia (platelet count,
109 × 109/L). Serum biochemistries, including aspar-
tate aminotransferase (40 U/L; normal, 8–40 U/L),
alanine aminotransferase (12U/L; normal, 4–44U/L),
alkaline phosphatase (167U/L; normal, 50–190U/L),
total bilirubin (0.8 mg/dL; normal, 0.1–1.2 mg/dL),
blood urea nitrogen (18 mg/dL; normal, 5–25 mg/
dL) and serum creatinine (0.9 mg/dL; normal, 0.7–
1.4 mg/dL) were all within normal limits, except for
lactate dehydrogenase which was elevated at 418 U/L
(normal, 120–140U/L). Coagulopathy was also noted
(prothrombin time, 14.0/10.5; international normal-
ized ratio, 1.33; activated partial thromboplastin time,
50.4/32.7).
Tests for autoimmune disease, including antinuclear
and anticardiolipin antibodies, as well as rheumatoid
factor, were negative. Serum triglyceride level (394mg/
dL; normal, 20–200 mg/dL), ferritin (4,690 ng/mL;
normal, 6–81 ng/mL) and soluble interleukin-2
receptor (7,402 pg/mL; normal, < 880 pg/mL) were
elevated. Bone marrow examinations revealed marked
hemophagocytosis without evidence of malignancy
(Figure 2). The diagnosis of HLH was made accord-
ing to the following criteria: fever, cytopenia, elevated
lactate dehydrogenase, hyperferritinemia, hepatosple-
nomegaly, and bone marrow hemophagocytosis.4
The patient’s fever and general condition responded
only fairly to 5 mg methasone every 8 hours and 2 con-
secutive days of 100 mg etoposide. Low grade fever
persisted for 2 weeks. At the end of this time, a sec-
ond bone marrow examination revealed minimal
large atypical lymphocyte aggregation and profound
hemophagocytosis.
Under the suspicion of lymphoma-associated HLH,
splenectomy was suggested for further diagnosis, but
the patient refused this treatment. As malignant lym-
phoma is the leading cause of adult HLH, the patient
underwent chemotherapy for lymphoma with the
CNOP regimen (cyclophosphamide 750 mg/m2,
mitoxantrone 10 mg/m2, vincristine 1.4 mg/m2,
prednisolone 40 mg/m2 for 5 days). Four days after
initiation of chemotherapy, the patient suffered from
acute left upper abdominal pain and received urgent
splenectomy because of spontaneous splenic rupture
with internal bleeding and hypovolemic shock.
Pathologic examination of the spleen confirmed the
diagnosis of NHL, diffuse large cell, B phenotype
with positive CD20 stain (Figure 3). Intraoperative
liver biopsy disclosed hemosiderosis, but no evidence
of lymphoma cell infiltration.
The patient’s fever subsided after chemotherapy,
and he recovered from the splenic rupture. He
received another 5 courses of chemotherapy with the
R-CNOP regimen (rituximab 375 mg/m2, cyclophos-
phamide 750 mg/m2, mitoxantrone 10 mg/m2, vin-
cristine 1.4 mg/m2, prednisolone 40 mg/m2 for
5 days), and was released in a stable condition. Over a
follow-up period of 12 months, there was no residual
disease or relapse.
Discussion
As a delicate filter to clear the blood of particulate
matter and senescent blood cells, the spleen is com-
monly involved in hematologic malignancies. For
example, half of all patients with Hodgkin’s disease
and a third of those with NHL have splenic involve-
ment,7 which greatly increase the difficulty in diag-
nosing true PSL. Splenic involvement can be part of a
Figure 1. Computed tomography of the abdomen shows an
enlarged spleen with multiple irregular and attenuated density
lesions.
Figure 2. Bone marrow aspiration smear reveals activated macro-
phages (arrows) with phagocytosis of hematopoietic cells, includ-
ing mature red blood cells, neutrophils and platelets (Wright and
Giemsa stain, 400×).
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diffuse dissemination of the lymphoma, however, the
spleen itself may be the primary site. Das Gupta et al2
restrictively defined PSL as a lymphoma involving only
the spleen and the splenic hilar lymph nodes, but not
the liver or other sites. Six months or more between
detection of splenic involvement and appearance of
lymphoma elsewhere is also required.2 Two less
restrictive definitions of PSL have also been proposed.
Skarin et al8 suggested diagnosis of PSL for any lym-
phoma with splenic involvement and splenomegaly as
a predominant feature. Kraemer et al9 further defined
PSL as lymphoma, presenting with splenomegaly, at
least bicytopenia, and in the absence of peripheral
adenopathy. Regardless of the definition, PSL is rare,
probably comprising less than 1% of NHL.1 Our
patient was diagnosed as having PSL by fulfilling the
criteria proposed by Skarin et al and Kraemer et al.
The most common presentation of PSL is
splenomegaly. Constitutional symptoms such as weight
loss, fever and night sweating are often noted.10
Diagnosis of PSL, however, is not easy. A study by
Kraus et al11 evaluated the diagnostic yield of splenec-
tomy in patients with unexplained splenomegaly or
splenic mass. Although malignancy, especially NHL,
is the most common diagnosis, splenectomy is seldom
used as a diagnostic maneuver because of its invasive-
ness and patients’ rejection of the treatment. Some
studies12 documented safe use of alternatives: splenic
fine needle aspiration and splenic core biopsy for
patients with splenomegaly or splenic mass, but these
procedures frequently result in splenic rupture with
fatal consequences. Inadequate specimens are another
concern. Even so, splenectomy is still the cornerstone
of diagnosis, remaining the main treatment modality
for PSL.
PSL shares similar clinical presentations with HLH,
including fever, splenomegaly, cytopenia, and elevated
lactate dehydrogenase, but they rarely occur together.
The presence of HLH greatly increases the difficulty
of diagnosing PSL. Eradication of the underlying dis-
ease is definitely the cornerstone of HLH treatment.
Since NHL is still the leading cause of adult HLH,5
Takahashi et al13 have suggested that without definite
etiology, HLH should be treated as lymphoma when
it is refractory to steroids.
After our patient’s refusal of diagnostic splenec-
tomy, we followed Takahashi et al’s suggestion and
treated him as an NHL-associated HLH patient with
systemic chemotherapy. Unfortunately, spontaneous
splenic rupture occurred soon after chemotherapy
began. Immediate splenectomy saved the patient’s life
and provided an accurate diagnosis of PSL. Sponta-
neous splenic rupture is a rare condition. According
to the criteria described by Orloff and Peskin in
1958,14 spontaneous rupture of a diseased spleen is
categorized as a pathologic rupture. Hematologic
malignancies, especially NHL, are the most common
underlying diseases.15 Congestion of the splenic
parenchyma by tumor cells, coagulation disorders,
and splenic infarction may explain the rupture.15 Our
patient had all of these risk factors.
Treatments for PSL include splenectomy, local
radiotherapy, and systemic chemotherapy. Splenectomy
is the most popular choice because it provides both
correct diagnosis and effective treatment. Local radio-
therapy is an option for patients diagnosed with PSL
if splenectomy is not feasible.16 Morel et al17 stated
that early splenectomy can improve survival for patients
tolerating adjuvant chemotherapy who recover from
cytopenia after surgery. Survival of PSL patients sig-
nificantly correlates to the stage of the disease,18 but
Xiros et al19 documented that median survival after
diagnostic splenectomy was 24 months regardless of
disease stage or adjuvant chemotherapeutic regimen.
A B
Figure 3. Histologic examination of the splenectomy specimen reveals: (A) diffuse and large atypical lymphocyte aggregations (hema-
toxylin & eosin, 400×); (B) positive CD20 staining (arrows) (400×).
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It is not clear whether splenectomy or systemic
chemotherapy is the better choice for initial PSL
treatment when PSL is combined with HLH. The
efficacy of adding rituximab to conventional chemother-
apeutic agents has not been proven either. Pathologic
spontaneous splenic rupture, however, is a potential
risk. Our case constitutes a successful experience in
using monoclonal antibodies and chemotherapeutic
agents to treat PSL combined with HLH. Long-term
observations of survival are still needed.
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